Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 12, 2013 (13 years ago)

Ketorolac Tromethamine Inj.

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: Either a loose crimp or no crimp was applied to the fliptop vials.

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Ketorolac Tromethamine Inj., USP, 30 mg vial, Rx only, Hospira, Inc., Lake Forest, IL 60045 USA, NDC 0409-3795-01

Affected NDC 0409-3795-01

Compare with the code on your package — it is the most precise check available.

Drug: Ketorolac

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Ketorolac Tromethamine
NDC 00409-3795
30 mg/mL Injection, Solution
Intramuscular|intravenous
Hospira, Inc. Rx
Recalling firm
Hospira, Inc.
NDC code
0409-3795-01
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-926-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ketorolac recalls

See all

Other recalls by Hospira, Inc.

All 2013 recalls
Class II · Moderate risk

DOBUTamine Injection

Discoloration: Firm received complaints of product discoloration and particulates.

Terminated Failed specification Hospira Inc. NDC 0409-2025-20 D-1500-2016